New combo therapy takes on tough myeloma
NCT ID NCT07093554
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tests a two-step treatment for people with multiple myeloma that has come back or stopped responding to other therapies. First, patients receive talquetamab, a drug that helps the immune system attack cancer cells. Then, they get an infusion of their own genetically modified immune cells (cilta-cel) to further fight the cancer. The study will enroll 31 participants and focus on whether this approach is safe and feasible.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Talquetamab and ciltacabtagene autoleucel (cilta-cel)
- What this could lead to
- If successful, this combination approach could offer a new treatment option for patients with hard-to-treat multiple myeloma.
- What could go wrong
- This is a very early (phase 1b) and small study (31 people). The main goal is safety, not yet effectiveness. There are risks of serious side effects from both drugs, including immune reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Froedtert & the Medical College of Wisconsin
RECRUITINGMilwaukee, Wisconsin, 53226, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered donor cells could outsmart relapsed myeloma
- Can a Triple-Drug cocktail tame resistant myeloma?
- Can a One-Two drug punch beat back Hard-to-Treat myeloma?
- CAR-T breakthroughs come with infection risks – new study aims to decode them
- Double-barreled CAR t therapy takes aim at hard-to-treat myeloma
- Can a drug stop dangerous side effects of new myeloma therapies?